Drotrecogin alfa (Activated) in severe sepsis: a systematic review of observational studies (Update of Report 29)
Nicolau I, Pan I, Xie X, McGregor M, Dendukuri N
Record ID 32012000901
English
Authors' recommendations:
• The mortality rates reported in the observational studies we reviewed, were higher than the rates previously reported
in RCTs (PROGRESS and ADDRESS).
• Studies that included a comparison group of patients not treated with DrotAA, generally concluded that there was a
beneficial effect of DrotAA treatment.
• The majority of studies reported being supported by the manufacturer.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.mcgill.ca/tau/files/tau/muhc_tau_2012_58_sepsis_a.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Sepsis
- Anti-Infective Agents
- Recombinant Proteins
- Protein C
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.